BioSpace News Archive

ESSS and Ansys are collaborating to provide an improved discrete element modeling workflow for quickly analyzing and assessing particle movement across numerous industrial applications.

Baebies , a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, today announced that the U.S. Food & Drug Administration (FDA) acknowledged the company’s Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on the FINDER ® 1.5 Instrument .

Lexaria Bioscience Corp. a global innovator in drug delivery platforms, will begin important new applied research and development study programs planned in 2021.

Lannett Company, Inc. (NYSE: LCI) (the “Company”) today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior secured notes due 2026 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1

Extending its ongoing commitment to caregivers through the Caregiver-Friendly Pharmacy program, and recognizing the significant toll COVID-19 has had on the caregiver community over the past year, Teva Canada unveiled new resources and programming to support the mental health challenges caregivers often experience.

- Introduces new resources to support and improve mental health of Caregivers - April 6, 2021 – National Caregiver Day Event – 12:00 PM EDT Free Live Virtual Class at 12:00 PM EDT today for caregivers focuses on importance of being resilient and how to access it from within; register via Eventbrite at: TevaCanada.com

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration on autism with researchers from the Seaver Autism Center for Research

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of NAVIGATEnash.com , its dedicated trial website.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has appointed Dr. Steven L. Wolf, a global expert in the field of Physical Therapy & Rehabilitation Medicine, as a consultant for its clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”).

- Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller , Ph.D., Chief Executive Officer, President, and Co-Founder will present at the annual Cell & Gene Meeting on the Mediterranean, which will be held virtually April 6-9, 2021 .